Related Experiment Videos
[Bone marrow micrometastases in colorectal cancers]
Fortschritte Der Medizin
|January 20, 1989
Summary
New immunocytochemical methods enable the detection of colorectal carcinoma micrometastases in bone marrow. Cytokeratin component 18 (CK2) identified these cells in 22 of 82 patients, improving diagnostic capabilities.
Area of Science:
- Oncology
- Immunohistochemistry
- Cell Biology
Context:
- Conventional diagnostic methods struggle to detect individual micrometastases or disseminated tumor cells.
- Bone marrow analysis is crucial for staging and prognosis in various cancers.
- Advances in immunocytochemistry offer enhanced cellular detection capabilities.
Purpose:
- To evaluate the utility of immunocytochemical investigation for detecting micrometastases in colorectal carcinoma patients.
- To determine the suitability of the monoclonal antibody cytokeratin component 18 (CK2) for identifying disseminated tumor cells.
- To analyze the incidence of CK2-positive cells in bone marrow relative to clinical and pathological factors.
Summary:
- Immunocytochemical analysis using the monoclonal antibody cytokeratin component 18 (CK2) successfully detected micrometastases in the bone marrow of colorectal carcinoma patients.
- CK2-positive cells, indicative of micrometastases, were identified in 22 out of 82 (26.8%) patients.
- The study explored the correlation between the presence of these micrometastases and primary tumor characteristics, including size, lymph node status, distant metastasis, tumor grade, and patient demographics.
Impact:
- This research highlights a novel immunocytochemical approach for detecting minimal residual disease in colorectal cancer.
- The findings may lead to improved diagnostic accuracy and more personalized treatment strategies for colorectal carcinoma patients.
- Enhanced detection of micrometastases can potentially refine prognostic assessments and guide therapeutic interventions.